Study of the Link Between Complement Activation and IgA Nephropathy Severity
University Hospital, Strasbourg, France
400 participants
May 9, 2022
OBSERVATIONAL
Conditions
Summary
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study. The main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.
Eligibility
Inclusion Criteria6
- Adult patients, male or female, with a biopsy proven IgA nephropathy.
- Primitive and secondary forms can be included
- Regardless of the date of diagnosis and the level of kidney function
- With or without past of kidney transplantation
- Followed in the Nephrology Department, Strasbourg University Hospital
- Signed informed consent
Exclusion Criteria3
- Active or recent infectious or inflammatory syndrome (<2 months), recent vaccination (<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (<2 months), current treatment with complement inhibitors
- Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)
- Subject under safeguard of justice, guardianship or curatorship
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05234463